These healthcare leaders still could perform well in the long run. Novo Nordisk has been facing several challenges that ...

Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced ...

Several anti-obesity drugs, including Ozempic, Wegovy and Mounjaro, have created buzz in the Indian markets. But are they really approved for use in India? What are their side-effects? And how much do ...

The study found that GLP-1 medications, in particular, showed significant weight regain after treatment discontinuation.

During the hearing, an official from Novo Nordisk will be questioned about the pricing they charge for Ozempic and ...

When glucagon-like peptide-1 receptor agonists (GLP-1s) like semaglutide (Wegovy) and liraglutide (Saxenda) were approved for ...

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company's senior executives for ...

The risks of the new weight-loss drugs can sound scary, and there’s lots of talk about side effects. What does evidence show?

India's anti-obesity drug market is valued at Rs 3,000-3,500 crore and is projected to grow nearly eightfold to Rs 25,000 ...

Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid ...

Editors: Story has been updated from original, with material from the president of the Arizona Obesity Organization. Slug: ...

A spokesperson said: “Results from the STEP trials demonstrate that weight regain is likely once medication is stopped.